Healthcare — Institutional Ownership & Hedge Fund Activity
Track hedge fund buying and selling activity in Healthcare stocks based on SEC 13F filings for Q1 2026.
Most Bought Healthcare Stocks
| # | Stock | Company | Funds Buying | Net $ Change |
|---|---|---|---|---|
| 1 | ASND | Ascendis Pharma A/S | 1 | +$22.2M |
| 2 | IMNM | Immunome, Inc. | 1 | +$178.5B |
| 3 | BEAT | HeartBeam, Inc. | 1 | +$1.1B |
| 4 | FHTX | Foghorn Therapeutics Inc. | 1 | +$11.3B |
| 5 | AVBP | ArriVent BioPharma, Inc. Common Stock | 1 | +$58.3B |
| 6 | NMRA | Neumora Therapeutics, Inc. Common Stock | 1 | +$4.0B |
| 7 | CGEM | Cullinan Therapeutics, Inc. | 1 | +$63.2B |
| 8 | HUMA | Humacyte, Inc. | 1 | +$7.5B |
| 9 | DSGN | Design Therapeutics, Inc. | 1 | +$22.7B |
| 10 | CRL | Charles River Laboratories International, Inc. | 1 | +$0 |
| 11 | CELC | Celcuity Inc. | 1 | +$60.5M |
| 12 | IMCR | Immunocore Holdings plc | 1 | +$19.8B |
| 13 | CTNM | Contineum Therapeutics, Inc. Class A Common Stock | 1 | +$8.7B |
| 14 | NEO | NeoGenomics, Inc. | 1 | +$147.9B |
| 15 | DNTH | Dianthus Therapeutics, Inc. | 1 | +$266.4B |
| 16 | CAI | Caris Life Sciences, Inc. | 1 | +$86.8B |
| 17 | KYMR | Kymera Therapeutics, Inc. | 1 | +$421.1B |
| 18 | ACRS | Aclaris Therapeutics, Inc. | 1 | +$27.8B |
| 19 | LXEO | Lexeo Therapeutics, Inc. Common Stock | 1 | +$29.3B |
| 20 | GLUE | Monte Rosa Therapeutics, Inc. | 1 | +$92.7B |
Most Sold Healthcare Stocks
| # | Stock | Company | Funds Selling | Net $ Change |
|---|---|---|---|---|
| 1 | DOCS | Doximity, Inc. | 1 | +$0 |
| 2 | LNSR | LENSAR, Inc. | 1 | +$0 |
| 3 | INGN | Inogen, Inc. | 1 | +$0 |
| 4 | BTMD | biote Corp. | 1 | +$0 |
| 5 | CDNA | CareDx, Inc | 1 | +$0 |
| 6 | GKOS | Glaukos Corporation | 1 | $-51.4M |
| 7 | MCRB | Seres Therapeutics, Inc. | 1 | +$0 |
| 8 | LH | Labcorp Holdings Inc. | 1 | +$0 |
| 9 | DAWN | Day One Biopharmaceuticals, Inc. | 1 | +$0 |
| 10 | AVIR | Atea Pharmaceuticals, Inc. | 1 | +$0 |
| 11 | LUNG | Pulmonx Corporation | 1 | +$0 |
| 12 | ANGO | AngioDynamics, Inc. | 1 | +$0 |
| 13 | CAH | Cardinal Health, Inc. | 1 | +$0 |
| 14 | LNTH | Lantheus Holdings, Inc. | 1 | +$0 |
| 15 | MRNA | Moderna, Inc. | 1 | +$0 |
| 16 | INMB | INmune Bio, Inc. | 1 | +$0 |
| 17 | DGX | Quest Diagnostics Incorporated | 1 | +$0 |
| 18 | HCAT | Health Catalyst, Inc. | 1 | +$0 |
| 19 | AUTL | Autolus Therapeutics plc | 1 | +$0 |
| 20 | HRTX | Heron Therapeutics, Inc. | 1 | +$0 |
Explore More
Data sourced from SEC 13F filings for Q1 2026. Filings are delayed up to 45 days after quarter end.